On Sunday, April 20th 2025, starting 8:30am GMT, there will be maintenance work that will involve the website being unavailable during parts of the day. We apologize for any inconvenience this may cause and appreciate your understanding.
We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline (1)
- Lipoprotein lipase biology
- Consequences of loss of LPL activity
- Genetic LPL deficiency
- Clinical phenotype of LPL deficiency
- Gene therapy for LPL deficient patients
- Outline (2)
- Gene replacement
- Vector - adeno-associated virus
- Transgene - LPLS447X
- AMT-010 vector
- Vector production
- Proof of principle in LPL deficient mice
- Proof of principle in LPL deficient mice - long term
- AMT010 in LPL deficient mice - dose dependency
- Feline LPL deficiency
- Vector administration
- Proof of principle in LPL deficient cats
- LPL deficient cats - antibodies development
- LPL deficient cats - immunosuppression (1)
- LPL deficient cats - immunosuppression (2)
- Gene delivery to myoblasts
- Infection of myoblasts with AMT010
- Conclusions for clinical trial
- Outline (3)
- Premonitoring study (1)
- Premonitoring study (2)
- Clinical trial
- Clinical trial - design & inclusion criteria
- Clinical trial - baseline characteristics
- Clinical trial - gene defects and baseline
- Administration of AMT-010
- Clinical trial - safety analyses
- Aknowledgements
Topics Covered
- No treatment for genetic lipoprotein lipase (LPL) deficiency
- This disorder has several specific characteristics which make it a feasible target for gene therapy approaches
- Development of LPL transgene delivery
- Use of adeno-associated virus
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kuivenhoven, J.A. (2008, November 24). Gene therapy as a therapeutic option for lipoprotein lipase deficiency [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 15, 2025, from https://doi.org/10.69645/UGZH8204.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jan Albert Kuivenhoven has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Gene therapy as a therapeutic option for lipoprotein lipase deficiency
A selection of talks on Cardiovascular & Metabolic
Hide